Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sampling design

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    54 result(s) found for: Sampling design. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2017-003790-34 Sponsor Protocol Number: DDD17COLSAM Start Date*: 2018-01-09
    Sponsor Name:KU Leuven - Drug Delivery and Disposition
    Full Title: Drug disposition in the human colon: sampling optimization
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000562-36 Sponsor Protocol Number: BIG2-06/N063D/EGF106708 Start Date*: 2007-05-04
    Sponsor Name:Novartis Pharma Services AG
    Full Title: ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) study. A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their comb...
    Medical condition: Operable primary breast cancer with over expression/ amplification of HER2.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) HU (Completed) FR (Completed) GB (Completed) SK (Completed) EE (Completed) CZ (Completed) DK (Completed) BE (Completed) DE (Completed) GR (Completed) NL (Completed) IT (Completed) ES (Completed) SI (Completed) BG (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005006-31 Sponsor Protocol Number: EML053774_002 Start Date*: 2007-04-03
    Sponsor Name:Merck Sante France
    Full Title: A randomized, stratified on age, parallel group design study to investigate the safety, tolerability and pharmacokinetics after a 60 minutes application of 4% lidocaine cream compared to EMLA® crea...
    Medical condition: Topical anesthesia of healthy skin before venous or subcutaneous puncture, before superficial cutaneous instrumental surgery or laser beam (tattoo or cutaneousangioma)
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-003511-31 Sponsor Protocol Number: V99P2 Start Date*: 2008-07-16
    Sponsor Name:Novartis Vaccines and Diagnostics GmbH & Co. KG
    Full Title: Phase I/II, Randomized, Observer-blind, Placebo-controlled, Single-Center Study of the Tolerability, Immunogenicity and Efficacy (following Helicobacter pylori infectious challenge) of Novartis’ In...
    Medical condition: no medical condition: healthy subjects
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-004002-21 Sponsor Protocol Number: Bio-Eq-20 Start Date*: 2021-11-26
    Sponsor Name:AOP Orphan Pharmaceuticals GmbH
    Full Title: A single center, open-label, two-period, non-randomized, paired-design study to compare steady-state plasma levels following switch from a 10 mg/ml treprostinil formulation to a 20 mg/ml treprostin...
    Medical condition: pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001009-26 Sponsor Protocol Number: DDD19GISAM Start Date*: 2019-09-10
    Sponsor Name:KU Leuven - Drug Delivery and Disposition
    Full Title: Gastrointestinal behaviour of mesalazine in healthy volunteers
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002455-97 Sponsor Protocol Number: 13381 Start Date*: 2016-10-19
    Sponsor Name:University of Southampton
    Full Title: Antibiotics for lower Respiratory Tract Infection in Children presenting in Primary Care
    Medical condition: Respiratory tract infections in children aged between 6 months and 12 years
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10066740 Acute respiratory tract infection LLT
    21.1 10021881 - Infections and infestations 10024968 Lower respiratory tract infection PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-004880-33 Sponsor Protocol Number: 18F-FDOPA-BUP-ESC Start Date*: 2023-01-20
    Sponsor Name:Medical University of Vienna, University Department of Psychiatry and Psychotherapy
    Full Title: Reward-specific changes of cerebral dopamine synthesis in healthy volunteers and depressed patients
    Medical condition: Major Depression
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002813-24 Sponsor Protocol Number: BAY94-8862/16538 Start Date*: 2016-11-15
    Sponsor Name:Bayer AG
    Full Title: Relative bioavailability study to investigate the pharmacokinetics, safety and tolerability of a single oral dose of finerenone 20 mg as suspension (pediatric formulation), intact tablet and crushe...
    Medical condition: Diabetic kidney disease
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002895-29 Sponsor Protocol Number: BAY94-8862/18290 Start Date*: 2016-10-28
    Sponsor Name:Bayer AG
    Full Title: Relative bioavailability study to investigate the pharmacokinetics, safety and tolerability of single oral doses of finerenone 1.25 mg and 5 x 0.25 mg oro-dispersible tablet (pediatric formulatio...
    Medical condition: Treatment of diabetic kidney disease (adults) and chronic kidney disease (children).
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-004919-11 Sponsor Protocol Number: FLAIR-i Start Date*: 2022-05-03
    Sponsor Name:Donders Institute for Brain, Cognition and Behaviour, Radboud University
    Full Title: The effect of colchicine on Food-reLAted effort-based decision making in brain and behavIouR in overweight and obesity: the FLAIR-i study.
    Medical condition: Low-grade inflammation in obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    24.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003394-15 Sponsor Protocol Number: VP-VEC-162-4201 Start Date*: 2016-06-28
    Sponsor Name:Vanda Pharmaceuitcals Inc.
    Full Title: OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS AND SAFETY OF TASIMELTEON IN TOTALLY BLIND CHILDREN AND ADOLESCENTS WITH NON-24-HOUR SLEEP- WAKE DISORDER
    Medical condition: This study will be an open-label, single dose, non-controlled trial to evaluate the pharmacokinetics and safety of tasimelteon in children who are 3 years to less than 18 years of age, totally blin...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10040984 Sleep disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005347-14 Sponsor Protocol Number: H2020/PHRC-N/2014/GB-01 Start Date*: 2016-08-25
    Sponsor Name:CHU DE NIMES
    Full Title: Efficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for controlling neuro-inflammation in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients: A randomized, double-blind, pla...
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-000720-98 Sponsor Protocol Number: RXC004/0001 Start Date*: 2017-06-19
    Sponsor Name:Redx Pharma plc
    Full Title: A Modular, Multi-Arm, Phase 1/2a, Adaptive Design Study To Evaluate The Safety And Tolerability Of RXC004, Alone And In Combination With Anti-Cancer Treatments, In Patients With Advanced Malignancies
    Medical condition: Patients with Advanced Malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-006168-30 Sponsor Protocol Number: RLH_Pentoxifylline_Dec2011 Start Date*: 2013-01-08
    Sponsor Name:R&D, Barts and The London NHS Trust
    Full Title: PEntoxifylline in Anaemia Resistant to erythropoietin (PEAR)
    Medical condition: We shall study patients with renal failure on dialysis. We shall particularly focus on patients with evidence of erythopoeitin stimulating agent (ESA) resistance.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004857 10014647 End stage renal failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003184-62 Sponsor Protocol Number: J1369 Start Date*: 2014-04-23
    Sponsor Name:Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Full Title: A phase I study of SGI-110 combined with irinotecan followed by a randomized phase II study of SGI-110 combined with irinotecan versus regorafenib in previously treated metastatic colorectal cancer...
    Medical condition: Previously treated metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010030 Colorectal cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002302-32 Sponsor Protocol Number: C16017 Start Date*: 2013-11-12
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: An Open-label, Multicenter, Phase 2 Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Follicular Lymphoma
    Medical condition: Follicular Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10029478 Nodular lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-001371-35 Sponsor Protocol Number: S241-GB-03 Start Date*: 2005-05-18
    Sponsor Name:Stiefel Laboratories Maidenhead Ltd (commonly known as Stiefel Laboratories International Division)
    Full Title: A Double-Blind, Placebo Controlled, Half-Head Design, CPO Solution Dose Ranging-Finding Study in Patients with Seborrhoeic Dermatitis of the Scalp
    Medical condition: Seborrhoeic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    8.0 10039793 LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003902-42 Sponsor Protocol Number: GePKHIS Start Date*: 2018-03-08
    Sponsor Name:Consorzio Futuro in Ricerca
    Full Title: F9 Genotype and PK Hemophilia B International Study
    Medical condition: Deficiency of coagulation factor IX (FIX; Hemophilia B); Hemophilia B patients treated with recombinant FIX (BeneFIX).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10053752 Hemophilia B with anti factor IX LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-001883-91 Sponsor Protocol Number: CLIN-60190-452 Start Date*: 2022-10-07
    Sponsor Name:Ipsen Bioscience Inc
    Full Title: A Phase I, Open Label, Randomised, Balanced, Single-dose, Two-period, Two-sequence Crossover-design Study to Evaluate Effects of Food on the Bioavailability of 80 mg Elafibranor (IPN60190) To-be-ma...
    Medical condition: This is a study to evaluate the effects of food on the bioavailability of elafibranor in healthy adult participants. It is part of a clinical development program for the IMP, the intended indicatio...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004871 10036680 Primary biliary cirrhosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 08 00:59:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA